Prime-boost immunization eliminates metastatic colorectal cancer by producing high-Avidity effector CD8+ T cells

Journal of Immunology

Volumn 198, Issue 9, 2017, Pages 3507-3514

  Xiang, Bo ^a   Baybutt, Trevor R ^a   Berman Booty, Lisa ^b   Magee, Michael S ^a,c   Waldman, Scott A ^a   Alexeev, Vitali Y ^a   Snook, Adam E ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c BLUEBIRD BIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AD5 VACCINE; ADENOVIRUS VACCINE; DNA VACCINE; GUANYLATE CYCLASE; GUANYLYL CYCLASE C; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; ATRIAL NATRIURETIC FACTOR RECEPTOR; ENTEROTOXIN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; RECEPTOR; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APICAL MEMBRANE; ARTICLE; BAGG ALBINO MOUSE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CD8+ T LYMPHOCYTE; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATIONAL STUDY; DNA IMMUNIZATION; EFFECTOR CELL; ELECTROPORATION; IMMUNE RESPONSE; IMMUNIZATION; METASTASIS; MOUSE; NONHUMAN; SPLEEN CELL; TUMOR IMMUNITY; ADENOVIRIDAE; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CELL CULTURE; COLORECTAL NEOPLASMS; CYTOTOXICITY; GENETICS; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; MUCOSAL IMMUNITY; PHYSIOLOGY; PROCEDURES; SECONDARY IMMUNIZATION; TRANSPLANTATION; TUMOR VOLUME;

ADENOVIRIDAE; ANIMALS; BIOMARKERS, TUMOR; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; COLORECTAL NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; IMMUNITY, MUCOSAL; IMMUNIZATION, SECONDARY; IMMUNOTHERAPY, ADOPTIVE; INTESTINAL MUCOSA; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, GUANYLATE CYCLASE-COUPLED; RECEPTORS, PEPTIDE; TUMOR BURDEN; VACCINES, DNA;

EID: 85018464544     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1502672     Document Type: Article

References (52)

1. Siegel, R., D. Naishadham, and A. Jemal. 2012. Cancer statistics, 2012. CA Cancer J. Clin. 62: 10-29.
2. Weir, G. M., R. S. Liwski, and M. Mansour. 2011. Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines. Cancers (Basel) 3: 3114-3142.
3. Yamada, A., T. Sasada, M. Noguchi, and K. Itoh. 2013. Next-generation peptide vaccines for advanced cancer. Cancer Sci. 104: 15-21.
4. Kantoff, P.W., C. S. Higano, N. D. Shore, E. R. Berger, E. J. Small, D. F. Penson, C. H. Redfern, A. C. Ferrari, R. Dreicer, R. B. Sims, et al. 2010. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363: 411-422.
5. Appaiahgari, M. B., and S. Vrati. 2012. Clinical development of IMOJEV -A recombinant Japanese encephalitis chimeric vaccine (JE-CV). Expert Opin. Biol. Ther. 12: 1251-1263.
6. Rollier, C. S., A. Reyes-Sandoval, M. G. Cottingham, K. Ewer, and A. V. Hill. 2011. Viral vectors as vaccine platforms: deployment in sight. Curr. Opin. Immunol. 23: 377-382.
7. Kutzler, M. A., and D. B. Weiner. 2008. DNA vaccines: ready for prime time? Nat. Rev. Genet. 9: 776-788.
8. Fioretti, D., S. Iurescia, V. M. Fazio, and M. Rinaldi. 2010. DNA vaccines: developing new strategies against cancer. J. Biomed. Biotechnol. 2010: 174378.
9. Davidson, A. H., J. L. Traub-Dargatz, R. M. Rodeheaver, E. N. Ostlund, D. D. Pedersen, R. G. Moorhead, J. B. Stricklin, R. D. Dewell, S. D. Roach, R. E. Long, et al. 2005. Immunologic responses to West Nile virus in vaccinated and clinically affected horses. J. Am. Vet. Med. Assoc. 226: 240-245.
10. Bergman, P. J., M. A. Camps-Palau, J. A. McKnight, N. F. Leibman, D. M. Craft, C. Leung, J. Liao, I. Riviere, M. Sadelain, A. E. Hohenhaus, et al. 2006. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 24: 4582-4585.
11. Sedegah, M., M. R. Hollingdale, F. Farooq, H. Ganeshan, M. Belmonte, Y. Kim, B. Peters, A. Sette, J. Huang, S. McGrath, et al. 2014. Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+ T cells targeting AMA1 class I epitopes. PLoS One 9: e106241.
12. Snook, A. E., L. C. Eisenlohr, J. L. Rothstein, and S. A. Waldman. 2007. Cancer mucosa antigens as a novel immunotherapeutic class of tumor-Associated antigen. Clin. Pharmacol. Ther. 82: 734-739.
13. Snook, A. E., P. Li, B. J. Stafford, E. J. Faul, L. Huang, R. C. Birbe, A. Bombonati, S. Schulz, M. J. Schnell, L. C. Eisenlohr, and S. A. Waldman. 2009. Lineagespecific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease. Cancer Res. 69: 3537-3544.
14. Snook, A. E., M. S. Magee, S. Schulz, and S. A. Waldman. 2014. Selective antigen-specific CD4(+) T-cell, but not CD8(+) T-or B-cell, tolerance corrupts cancer immunotherapy. Eur. J. Immunol. 44: 1956-1966.
15. Snook, A. E., B. J. Stafford, P. Li, G. Tan, L. Huang, R. Birbe, S. Schulz, M. J. Schnell, M. Thakur, J. L. Rothstein, et al. 2008. Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. J. Natl. Cancer Inst. 100: 950-961.
16. Witek, M., E. S. Blomain, M. S. Magee, B. Xiang, S. A. Waldman, and A. E. Snook. 2014. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C. Int. J. Radiat. Oncol. Biol. Phys. 88: 1188-1195.
17. Marszalowicz, G. P., A. E. Snook, M. S. Magee, D. Merlino, L. D. Berman-Booty, and S. A. Waldman. 2014. GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer. Oncotarget 5: 9460-9471.
18. Charney, A. N., R. W. Egnor, J. T. Alexander-Chacko, V. Zaharia, E. A. Mann, and R. A. Giannella. 2001. Effect of E. coli heat-stable enterotoxin on colonic transport in guanylyl cyclase C receptor-deficient mice. Am. J. Physiol. Gastrointest. Liver Physiol. 280: G216-G221.
19. Guarino, A., M. B. Cohen, G. Overmann, M. R. Thompson, and R. A. Giannella. 1987. Binding of E. coli heat-stable enterotoxin to rat intestinal brush borders and to basolateral membranes. Dig. Dis. Sci. 32: 1017-1026.
20. Kuhn, M., K. Adermann, J. Jähne, W. G. Forssmann, and G. Rechkemmer. 1994. Segmental differences in the effects of guanylin and Escherichia coli heat-stable enterotoxin on Cl-secretion in human gut. J. Physiol. 479: 433-440.
21. Carrithers, S. L., M. T. Barber, S. Biswas, S. J. Parkinson, P. K. Park, S. D. Goldstein, and S. A. Waldman. 1996. Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proc. Natl. Acad. Sci. USA 93: 14827-14832.
22. Valentino, M. A., J. E. Lin, A. E. Snook, P. Li, G. W. Kim, G. Marszalowicz, M. S. Magee, T. Hyslop, S. Schulz, and S. A. Waldman. 2011. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice. J. Clin. Invest. 121: 3578-3588.
23. Gong, R., C. Ding, J. Hu, Y. Lu, F. Liu, E. Mann, F. Xu, M. B. Cohen, and M. Luo. 2011. Role for the membrane receptor guanylyl cyclase-C in attention deficiency and hyperactive behavior. Science 333: 1642-1646.
24. Birbe, R., J. P. Palazzo, R. Walters, D. Weinberg, S. Schulz, and S. A. Waldman. 2005. Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum. Pathol. 36: 170-179.
25. Schulz, S., T. Hyslop, J. Haaf, C. Bonaccorso, K. Nielsen, M. E. Witek, R. Birbe, J. Palazzo, D. Weinberg, and S. A. Waldman. 2006. A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin. Cancer Res. 12: 4545-4552.
26. Snook, A. E., M. S. Magee, G. P. Marszalowicz, S. Schulz, and S. A. Waldman. 2012. Epitope-Targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C. Cancer Immunol. Immunother. 61: 713-723.
27. Igoucheva, O., M. Grazzini, A. Pidich, D. M. Kemp, M. Larijani, M. Farber, J. Lorton, U. Rodeck, and V. Alexeev. 2013. Immunotargeting and eradication of orthotopic melanoma using a chemokine-enhanced DNAvaccine. Gene Ther. 20: 939-948.
28. Chen, P. W., M. Wang, V. Bronte, Y. Zhai, S. A. Rosenberg, and N. P. Restifo. 1996. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-Associated antigen. J. Immunol. 156: 224-231.
29. Magee, M. S., C. L. Kraft, T. S. Abraham, T. R. Baybutt, G. P. Marszalowicz, P. Li, S. A. Waldman, and A. E. Snook. 2016. GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity. Oncoimmunology 5: e1227897.
30. Sardesai, N. Y., and D. B. Weiner. 2011. Electroporation delivery of DNA vaccines: prospects for success. Curr. Opin. Immunol. 23: 421-429.
31. Mathiesen, I. 1999. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther. 6: 508-514.
32. Plesa, G., A. E. Snook, S. A. Waldman, and L. C. Eisenlohr. 2008. Derivation and fluidity of acutely induced dysfunctional CD8+ T cells. J. Immunol. 180: 5300-5308.
33. Zhong, S., K. Malecek, L. A. Johnson, Z. Yu, E. Vega-Saenz de Miera, F. Darvishian, K. McGary, K. Huang, J. Boyer, E. Corse, et al. 2013. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proc. Natl. Acad. Sci. USA 110: 6973-6978.
34. Couzin-Frankel, J. 2013. Breakthrough of the year 2013. Cancer immunotherapy. Science 342: 1432-1433.
35. John, R. M., and H. Ross. 2010. The global economic cost of cancer. Available at: https://old.cancer.org/acs/groups/content/@internationalaffairs/documents/document/acspc-026203.pdf.
36. American Cancer Society. 2015. Cancer facts & figures 2015. Available at: https://old.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf.
37. Centers for Disease Control and Prevention. 1999. Impact of vaccines universally recommended for children-United States, 1990-1998. MMWR Morb. Mortal. Wkly. Rep. 48: 243-248.
38. Makedonas, G., and M. R. Betts. 2006. Polyfunctional analysis of human T cell responses: importance in vaccine immunogenicity and natural infection. Springer Semin. Immunopathol. 28: 209-219.
39. Betts, M. R., M. C. Nason, S. M. West, S. C. De Rosa, S. A. Migueles, J. Abraham, M. M. Lederman, J. M. Benito, P. A. Goepfert, M. Connors, et al. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107: 4781-4789.
40. Foley, M. H., T. Forcier, E. McAndrew, M. Gonzalez, H. Chen, B. Juelg, B. D. Walker, and D. J. Irvine. 2014. High avidity CD8+ T cells efficiently eliminate motile HIV-infected targets and execute a locally focused program of anti-viral function. PLoS One 9: e87873.
41. Tansiri, Y., S. L. Rowland-Jones, J. Ananworanich, and P. Hansasuta. 2015. Clinical outcome of HIV viraemic controllers and noncontrollers with normal CD4 counts is exclusively determined by antigen-specific CD8+ T-cell-mediated HIV suppression. PLoS One 10: e0118871.
42. Belyakov, I. M., B. Moss, W. Strober, and J. A. Berzofsky. 1999. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl. Acad. Sci. USA 96: 4512-4517.
43. Belyakov, I. M., M. A. Derby, J. D. Ahlers, B. L. Kelsall, P. Earl, B. Moss, W. Strober, and J. A. Berzofsky. 1998. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc. Natl. Acad. Sci. USA 95: 1709-1714.
44. Belyakov, I. M., J. D. Ahlers, B. Y. Brandwein, P. Earl, B. L. Kelsall, B. Moss, W. Strober, and J. A. Berzofsky. 1998. The importance of local mucosal HIVspecific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. J. Clin. Invest. 102: 2072-2081.
45. Porgador, A., K. R. Irvine, A. Iwasaki, B. H. Barber, N. P. Restifo, and R. N. Germain. 1998. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J. Exp. Med. 188: 1075-1082.
46. Cho, J. H., J. W. Youn, and Y. C. Sung. 2001. Cross-priming as a predominant mechanism for inducing CD8(+) T cell responses in gene gun DNA immunization. J. Immunol. 167: 5549-5557.
47. Ambriović, A., M. Adam, M. Monteil, D. Paulin, and M. Eloit. 1997. Efficacy of replication-defective adenovirus-vectored vaccines: protection following intramuscular injection is linked to promoter efficiency in muscle representative cells. Virology 238: 327-335.
48. Matsumoto, Y., H. Matsuo, H. Sakuma, I. K. Park, Y. Tsukada, K. Kohyama, T. Kondo, S. Kotorii, and N. Shibuya. 2006. CDR3 spectratyping analysis of the TCR repertoire in myasthenia gravis. J. Immunol. 176: 5100-5107.
49. Tumeh, P. C., C. L. Harview, J. H. Yearley, I. P. Shintaku, E. J. Taylor, L. Robert, B. Chmielowski, M. Spasic, G. Henry, V. Ciobanu, et al. 2014. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515: 568-571.
50. Hu, Z., J. Wang, Y. Wan, L. Zhu, X. Ren, S. Qiu, Y. Ren, S. Yuan, X. Ding, J. Chen, et al. 2014. Boosting functional avidity of CD8+ T cells by vaccinia virus vaccination depends on intrinsic T-cell MyD88 expression but not the inflammatory milieu. J. Virol. 88: 5356-5368.
51. Ranasinghe, C., S. J. Turner, C. McArthur, D. B. Sutherland, J. H. Kim, P. C. Doherty, and I. A. Ramshaw. 2007. Mucosal HIV-1 pox virus prime-boost immunization induces high-Avidity CD8+ T cells with regime-dependent cytokine/granzyme B profiles. J. Immunol. 178: 2370-2379.
52. Snook, A., T. Baybutt, M. Mastrangelo, N. Lewis, S. Goldstein, W. Kraft, Y. Oppong, T. Hyslop, R. Myers, V. Alexeev, et al. 2015. A phase I study of Ad5-GUCY2C-PADRE in stage I and II colon cancer patients. J. Immunother. Cancer 3 (Suppl. 2): P450.